1 / 5

MDUFMA Stakeholders Meeting – Performance Goals November 17, 2005

MDUFMA Stakeholders Meeting – Performance Goals November 17, 2005. Marlene Valenti, Vice President of Regulatory Affairs, Cordis Corporation. Performance Goals. Mandated under 2002 Medical Device User Fee and Modernization Act (MDUFMA)

Download Presentation

MDUFMA Stakeholders Meeting – Performance Goals November 17, 2005

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. MDUFMA Stakeholders Meeting – Performance GoalsNovember 17, 2005 Marlene Valenti, Vice President of Regulatory Affairs, Cordis Corporation

  2. Performance Goals • Mandated under 2002 Medical Device User Fee and Modernization Act (MDUFMA) • Intent was to reduce the amount of time from submission to market • Includes decision goals and cycle goals • FDA met most of 2005 Performance Goals • AdvaMed commends FDA for this achievement

  3. Performance Goals • Does Current Process Achieve the Original Intent? • FDA Response: In some cases and some cases unintended consequences • Industry Response: Very Infrequently

  4. Industry Perspective Substantial increase in non-approvable letters for PMA Supplements FY 2003: 31 out of 203 or ~ 15% FY 2004: 43 out of 103 or ~ 42% FY 2005: Not available, suspect it may be higher Increase in not-substantially equivalent (NSE’s) decisions for 510 (k) submissions Performance Goals

  5. Performance Goals • Path Forward • More guidance documents needed • Release of PMA Change Guidance document will provide transparency on what type of submission is required • AdvaMed willing to work in a collaborative manner to develop innovative ways to improve process

More Related